Bank of America has revised its price target for SpringWorks Therapeutics (SWTX, Financial), reducing it from $87 to $84 while maintaining a Buy rating on the company's shares. This adjustment reflects broader market considerations as investors prepare for the upcoming Q1 earnings season.
The primary focus for analysts, including those covering small to mid-cap biotech firms like SpringWorks, will be on the commercial launches that are expected to drive performance. However, they will also be keeping a close eye on additional factors that could influence market sentiment. These include discussions around pharmaceutical tariffs, tax implications, and the turnover within the FDA, all of which could present challenges or opportunities for companies in the biotech sector.
SpringWorks Therapeutics remains a key player in the industry, and with its maintained Buy rating, Bank of America continues to show confidence in the firm's growth potential despite the slight adjustment in its price target.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for SpringWorks Therapeutics Inc (SWTX, Financial) is $72.50 with a high estimate of $84.00 and a low estimate of $63.00. The average target implies an upside of 92.10% from the current price of $37.74. More detailed estimate data can be found on the SpringWorks Therapeutics Inc (SWTX) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, SpringWorks Therapeutics Inc's (SWTX, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
